drugset / Trial / NCT00761007
Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of the study is to evaluate the benefit of treatment with oral dose of Ibodutant (code: MEN 15596) on IBS symptoms and the safety and tolerability of this therapy.
Timeline
- Start
- 2008-07
- Primary completion
- 2009-02
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibodutant | Small molecule | 10 mg | Oral |
| Subject | Ibodutant | Small molecule | 30 mg | Oral |
| Subject | Ibodutant | Small molecule | 60 mg | Oral |